DANIEL ERNESTO
CASTELLANO GAUNA
Profesor asociado de Ciencias de la Salud
Jesús
García-Donas Jiménez
Publicacions en què col·labora amb Jesús García-Donas Jiménez (13)
2022
-
Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study
Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34
-
Logical Imputation to Optimize Prognostic Risk Classification in Metastatic Renal Cell Cancer
Kidney Cancer, Vol. 6, Núm. 3, pp. 169-178
-
Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group
Clinical Genitourinary Cancer, Vol. 20, Núm. 4, pp. 388.e1-388.e10
-
Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy
ESMO Open, Vol. 7, Núm. 2
2018
-
A genetic polymorphism in ctla-4 is associated with overall survival in sunitinib-treated patients with clear cell metastatic renal cell carcinoma
Clinical Cancer Research, Vol. 24, Núm. 10, pp. 2350-2356
2017
-
Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer—GEnetic- and tumor-related biomarkers for response and toxicity
Urologic Oncology: Seminars and Original Investigations, Vol. 35, Núm. 8, pp. 529.e9-529.e16
-
Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma
Pharmacogenetics and Genomics, Vol. 27, Núm. 6, pp. 227-231
-
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
The Lancet Oncology, Vol. 18, Núm. 5, pp. 672-681
-
Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients
Oncotarget, Vol. 8, Núm. 1, pp. 1204-1212
-
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Cancer Treatment Reviews, Vol. 53, pp. 79-97
2016
2015
-
Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma
European Journal of Clinical Pharmacology, Vol. 71, Núm. 12, pp. 1477-1484
-
Pazopanib in pretreated advanced neuroendocrine tumors: A phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)
Annals of Oncology, Vol. 26, Núm. 9, pp. 1987-1993